| By PR Newswire |
Article Rating: |
|
| December 24, 2012 08:30 AM EST |
Reads: |
211 |
SAN DIEGO, Calif., Dec. 24, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the JP Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 8, 2013 at 10:30 a.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
|
Orexigen Contact:
|
Media Contact:
|
|
McDavid Stilwell
|
Denise Powell
|
|
VP, Corporate Communications and Business Development
|
WCG
|
|
(858) 875-8629
|
(510) 703-9491
|
SOURCE Orexigen Therapeutics, Inc.
